Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 37Recruiting 13Terminated 3Completed 3Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 28Carboplatin 13Nivolumab 12Cisplatin 12atezolizumab 10Paclitaxel 10venetoclax 9Ipilimumab 9Radiotherapy 8Pemetrexed 8Docetaxel 8fludarabine 7durvalumab 7Specimen Handling 7Gemcitabine 7Cyclophosphamide 7Bevacizumab 7fludarabine phosphate 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6tislelizumab 5enzalutamide 5Trastuzumab 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5tazemetostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × ibrutinib × 90 days × Clear all
NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

University of California, San Diego

Phase 2 Terminated
5 enrolled 9 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06271616 2026-05-22

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Mayo Clinic

Phase 2 Terminated
2 enrolled

Bronchiolitis Obliterans Syndrome

NCT03506373 2026-05-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡